Our next panel, “Vision for the Future: Dry AMD, Other Greenfield Opportunities & Late Stage Stories to Shake Things Up,” featured Rachelle Jacques, President & CEO of Akari Therapeutics, Plc, Nathan L. Mata, PhD, CSO of Belite Bio, Dr. Daphne Haim-Langford, PhD, Founder & CEO of Tarsier Pharma, and Raul Trillo, MD, MBA, CCO of Vyluma. The panel was moderated by Cantor’s Jennifer Kim and Kristen Kluska.

• Akari is developing long-acting PAS-nomacopan (a bispecific recombinant inhibitor of complement C5 and LTB4) in geographic atrophy (GA). Lead asset nomacopan remains on track for an expected data readout in the Phase 3 Part A trial in severe pediatric HSCT-TMA in 1H23

• Tarsier is developing product candidates based on its TRS platform technology (which aims to approach inflammatory diseases from within the immune system), with TRS01 eye drops in Phase 3 development for the treatment of non-infectious anterior uveitis including uveitic glaucoma, and TRS02 IVT injections in IND-enabling studies for multiple retinal diseases

• Belite’s lead asset, LBS-008 (tinlarebant), is being developed as a novel oral once-a-day therapy for the treatment of Stargardt Disease (STGD1) and dry age-related macular degeneration (dry AMD), with enrollment in the Phase 3 dry AMD trial expected to begin in 1H23

• Vyluma most recently announced encouraging Phase 3 CHAMP top-line results for NVK002 (low-dose, preservative-free atropine eye drop) as a potential treatment for the progression of myopia in children, with plans to submit a NDA to the FDA as early as 1Q23

#Cantor #Cantorfitzgerald #Cantorhealthcare #Cantorconferenceseries #Dermatology #Opthalmology #Medtech #Diagnostic